The PD-1/PD-L1 Axis and Co-signaling Networks: Orchestrating T Cell Responses in Cancer and Autoimmunity
Resource:https://www.globecancer.com/azzx/show.php?itemid=15812
>> Scroll to view
| Drug Strategy | Strategy Type | Representative Drugs / Regimens | Core Mechanism / Objective |
|---|---|---|---|
|
PD-L1-targeting ADC
|
ADC
|
1. PD-L1 ADC: Henlius HLX43
2. PD-L1/αvβ6 integrin BsADC: Alphamab JSKN022
|
1. Target PD-L1 and achieve targeted killing through the cytotoxic payload of ADC
2. Dual targeting of PD-L1 and αvβ6 integrin to enhance tumor targeting and killing efficacy
|
|
PD-1 Plus: BsAb
|
Immune Escape Inhibition + Anti-angiogenesis
|
Simultaneously block PD-1-mediated immune escape signals, inhibit VEGF-mediated tumor angiogenesis, improve the tumor microenvironment, and enhance immunotherapeutic efficacy.
|
|
|
Immune Escape Inhibition + Immune Agonism
|
While blocking immune escape, activate immune effector cells such as T cells through the IL-2/4-1BB pathway to overcome immunotherapy resistance.
|
||
|
Multiple Immune Escape Inhibition
|
Simultaneously block multiple immune checkpoint pathways including PD-1, TIGIT, and CTLA-4 to strengthen the inhibition of immune escape.
|
||
|
Combination of PD-1/PD-L1 Inhibitor and ADC
|
Combination Therapy
|
Leverage the targeted killing effect of ADC and the immune activation function of PD-1/PD-L1 inhibitor to achieve synergistic antitumor effect and improve treatment response.
|
Human PD-L1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 98% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human PD-L1, His Tag (Cat. No. PD1-H5229) is more than 90% and the molecular weight of this protein is around 30-50kDa verified by SEC-MALS.
Request Report
Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 2 μg/mL (100 μL/well) can bind Human PD-L2, Mouse IgG1 Fc Tag (Cat. No. PD2-H52A5) with a linear range of 10-156 ng/mL (Routinely tested).
Request Protocol
Human PD-1, Fc Tag (Cat. No. PD1-H5257) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 3.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Request Protocol
Loaded Human PD-1, Fc Tag, low endotoxin (Cat. No. PD1-H5257) on Protein A Biosensor, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 5.3 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
Request Protocol
Immobilized cell surface PD-1 (5x104 of cells per well) can bind Human PD-L1, Fc Tag (Cat. No. PD1-H5258) with an EC50 of 0.029 μg/mL (Routinely tested).
Request Protocol
Immobilized Biotinylated Human PD-L1, Avitag,His Tag (Cat. No. PD1-H82E5) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Anti-PD-L1 MAb, Human IgG1 with a linear range of 0.2-3 ng/mL (Routinely tested).
Request Protocol
Anti-Human PD-L1 Mab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 0.286 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Request Protocol
Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 5 μg/mL, add increasing concentrations of Cadonilimab (PD-1 x CTLA-4 bispecific antibody) and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.99 ng/mL (Routinely tested).
Request Protocol
Immobilized Human VEGF165, His Tag (Cat. No. VE5-H5248) at 2 μg/mL, add increasing concentrations of Ivonescimab and then add Biotinylated Human PD-1 Protein, Avitag,His Tag (Cat. No. PD1-H82E4) at 2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.17 ng/mL (Routinely tested).
Flow Cytometry assay shows that Human PD-1 Protein, Fc Tag (Cat. No. PD1-H5257) can bind to 293 cell overexpressing human PD-L1. The concentration of PD-1 used is 1 μg/mL (Routinely tested).
Request Protocol
FACS analysis shows that the binding of Human PD-L1, Fc Tag (Cat. No. PD1-H5258) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing Anti-PD-L1 antibody. The concentration of PD-L1 used is 10 μg/mL. The IC50 is 12.92 μg/mL (Routinely tested).
Request Protocol
The Human PD-1 / PD-L1 Inhibitor Screening Kit (TR-FRET) (Cat. No. FRT-P019) is suitable for the detection of PD1/PD-L1 inhibitors. It shows that both Atezolizumab, Nofazinlimab and Pembrolizumab exhibit good inhibitory activity in this TR-FRET competition assay.
Request Protocol
Serial dilutions of Anti-PD-L1 Neutralizing antibody (Cat. No. EP133) (1:1 serial dilution, from 2 μg/mL to 0.015625μg/mL) was added into PD-L1: Biotinylated PD-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Request Protocol
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| IO-120 | IO-120 | Io Biotech Aps | Details | ||
| IMGS-001 | IMGS-001 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms | Details |
| IO-120/ IO-103 (IO Biotech) | IO-120/IO-103; IO-120+IO-103 | Phase 2 Clinical | Io Biotech Inc | Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| 89Zr-KN035(Wuxi No. 4 People's Hospital) | Clinical | Wuxi No. 4 People | Solid tumours | Details | |
| CTB-1 | CTB-1 | Clinical | GTS Biotech LLC | Neoplasms | Details |
| 18F-BMS-986192 | BMS-986192-[18F] | Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| Durvalumab/Selumetinib sulfate | Phase 1 Clinical | Astrazeneca Plc | Neoplasms | Details | |
| Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) | Phase 1 Clinical | Jiangsu Huaiyu Pharmaceutical Co Ltd | Solid tumours | Details | |
| Garivulimab | BGB-A333 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours; Neoplasms | Details |
| BJ-005 | BJ-005 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Lymphoma | Details |
| SG12473 | SG12473; SG-12473 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
| IBI-323(Innovent Biologics) | IBI-323 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| IMM2505 | IMM2505; IMM-2505 | Phase 1 Clinical | SunHo (China) BioPharmaceutical Co Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours | Details |
| QLS31901 | QLS-31901; QLS31901 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | Details |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms; Pleural Effusion, Malignant | Details | |
| CCX-559 | CCX-559 | Phase 1 Clinical | Chemocentryx Inc | Solid tumours; Neoplasms | Details |
| Ragistomig | ABL-503; TJ-L14B/ABL503; ABL503; TJ-L14B | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours | Details |
| GS-19 | GT-90008; GS-19; GS-19-PLB-1C | Phase 1 Clinical | Gensun Biopharma Inc | Solid tumours | Details |
| TST-005 | TST-005; TST005 | Phase 1 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd | Solid tumours; Neoplasms; Papillomavirus Infections | Details |
| BR-102 | BR102 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| AN-4005 | AN-4005 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
| PF-07257876 | Phase 1 Clinical | Pfizer Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details | |
| TT-00420/Atezolizumab | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Gastrointestinal Neoplasms | Details | |
| CA-170 | CA-170; AUPM-170 | Phase 1 Clinical | Aurigene | Solid tumours | Details |
| IMM-2520 | IMM-2520 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| FS222 mAb² (F-star Therapeutics) | FS-222 | Phase 1 Clinical | F-star Beta Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) | BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1 | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Solid tumours; Neoplasms; Melanoma; Uterine Cervical Neoplasms | Details |
| CN-202 | CN-202 | Phase 1 Clinical | Curon Biopharmaceutical Ltd | Solid tumours; Hematologic Neoplasms | Details |
| SHS-006(Nanjing Sanhome Pharmaceutical) | SHS-006; SH-006; SH006 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Solid tumours | Details |
| SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Neoplasms | Details |
| Gallium [68Ga] Natan recombinant PD-L1 single domain antibody | SNA-002; 68Ga-NOTA-SNA002 | Phase 1 Clinical | Smartnuclide Biopharma | Solid tumours; Neoplasms; Contrast agents | Details |
| 706-3SBio | SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody | Phase 1 Clinical | 3sbio Inc | Solid tumours; Composite Lymphoma; Neoplasms; Lymphoma | Details |
| CHECKvacc | CF33-hNIS-antiPDL1 | Phase 1 Clinical | Imugene Ltd, City Of Hope National Medical Center | Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
| SG-1408 | SG-1408; SG1408 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours | Details |
| CS-23546 | CS-23546; CS23546 | Phase 1 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Neoplasms; Immune System Diseases | Details |
| BPI-371153 | BPI-371153 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| DR-30206 | DR-30206 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Solid tumours | Details |
| ASC-61 | ASC-61 | Phase 1 Clinical | Ascletis Pharma Inc | Solid tumours; Neoplasms | Details |
| SGN-PDL1V | SGN-PDL1V; PF-08046054 | Phase 1 Clinical | Seagen Inc | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| QL-415 | QL-415 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| HS-10386 | HS-10386 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Solid tumours | Details |
| HBM-9027 | HBM-9027; HBM9027 | Phase 1 Clinical | Harbour Biomed | Solid tumours; Neoplasms | Details |
| Ori-Bs-001 | Ori-Bs-001 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Serositis; Ascites | Details | |
| HK-010 | HK-010; HK010 | Phase 1 Clinical | Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd | Neoplasms | Details |
| RAD-203 | RAD-203 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| 177Lu-RAD204 | RAD-204; 177Lu-RAD204; 177Lu-anti-PD-L1 sdAb | Phase 1 Clinical | Radiopharm Theranostics Ltd | Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AUR-106 | AUR-106 | Phase 1 Clinical | Aurigene Discovery Technologies Ltd | Kidney Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant anti-PD-L1/TGF-β bifunctional fusion protein | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Solid tumours | Details | |
| B-901 | B-901; B901 | Phase 1 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours | Details |
| KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
| SPX-303 | SPX-303 | Phase 1 Clinical | SparX Biopharmaceutical Corp | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck | Details |
| ND-021 | ND-021; NM21-1480; CS-2006; CS2006 | Phase 1 Clinical | Numab Therapeutics Ag, Cstone Pharmaceuticals | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| BAT-7205 | BAT7205; BAT-7205 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasm Metastasis | Details |
| YL-222 | YL222; YL-222 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| PMI-06 | PMI06; PMI-06 | Phase 1 Clinical | Precision Molecular Inc | Carcinoma, Non-Small-Cell Lung | Details |
| A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | Details |
| LW-347 | LW-347 | Phase 1 Clinical | Shanghai Longwood Biopharmaceuticals Co Ltd | Neoplasms | Details |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | Details |
| CVL006 | CVL006; B006 | Phase 1 Clinical | Fukang (Shanghai) Health Technology Co Ltd | Solid tumours; Neoplasms | Details |
| DCR-PDL1 | DCR-PDL1 | Phase 1 Clinical | Dicerna Pharmaceuticals Inc | Solid tumours | Details |
| Naptumomab estafenatox/Durvalumab | NTX-352 | Phase 1 Clinical | Neotx Therapeutics Ltd | Solid tumours | Details |
| Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company | Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| Pd-1-pik | Pd-1-pik | Phase 1 Clinical | Huashan Hospital Affiliated To Fudan University | Glioblastoma | Details |
| IBC-Ab002 | IBC-Ab002 | Phase 1 Clinical | ImmunoBrain Checkpoint Inc | Alzheimer Disease | Details |
| CTX-8371 | CTX-8371 | Phase 1 Clinical | Compass Therapeutics LLC | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Hodgkin Disease; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| ABL-501 | ABL-501 | Phase 1 Clinical | Abl Bio Inc | Solid tumours | Details |
| IMGS-001 | IMGS-001 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms | Details |
| Q-1801 | Q-1801; Q 1801 | Phase 1 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours | Details |
| QL-301 | QL-301 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| Xirestomig | ATG-101; ATG101; YN051 | Phase 1 Clinical | The Origin Cell Technology Group Co Ltd | Solid tumours; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Non-Hodgkin | Details |
| BH-3120 | BH-3120 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Solid tumours | Details |
| TS-1905 | TS-1905; LY-01019; BA-1201 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| CYTO-102 | CYTO-NK-102; CYTO-102; COH06 | Phase 1 Clinical | CytoImmune Therapeutics Inc | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| LP-008 | LP-008 | Phase 1 Clinical | Lepu Biopharma Co Ltd | Solid tumours | Details |
| SIM-0237 | SIM-0237; SIM-237 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
| AB-101 (Arbutus Biopharma) | AB-101 (Arbutus Biopharma) | Phase 1 Clinical | Arbutus Biopharma Corp | Hepatitis B, Chronic; Hepatitis B | Details |
| anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Hormone-Resistant Prostate Neoplasms | Details | |
| anti-PD-L1 CSR T-cell therapy (Marino Biotechnology) | Phase 1 Clinical | Beijing Marino Biotechnology Co Ltd | Glioblastoma; Neoplasms | Details | |
| dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Ovarian Neoplasms; Stomach Neoplasms; Peritoneal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details | |
| Simridarlimab | IBI-322; IBI322 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Hematologic Neoplasms; Bone Marrow Neoplasms; Solid tumours; Neoplasms; Lymphoma, T-Cell; Lymphoma; Leukemia, Myeloid, Acute | Details |
| Betifisolimab | MSB-2311 | Phase 1 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd | Solid tumours | Details |
| IMMH-010 | IMMH-010 | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| Opucolimab | HLX-20 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Solid tumours; Neoplasms | Details |
| INCB-086550 | INCB-086550; INCB-86550 | Phase 1 Clinical | Incyte Corp | Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| MCLA-145 | MCLA-145 | Phase 1 Clinical | Incyte Corp, Merus Nv | Solid tumours; Lymphoma, B-Cell; Neoplasms | Details |
| LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs Inc, Takeda Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Carcinoma, Transitional Cell; Carcinoma, Basosquamous; Astrocytoma; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Lodapolimab | LY-3300054 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| 89Zr-DFO-Atezolizumab | 89Zr-DFO-Atezolizumab | Phase 1 Clinical | The University Of Texas Southwestern Medical Center | Carcinoma, Renal Cell; Diagnostic agents | Details |
| Emdifen | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences | Solid tumours | Details | |
| Lesabelimab | BC-003 | Phase 2 Clinical | Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd | Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Penile Neoplasms | Details |
| ABSK-043 | ABSK043 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
| PM-8003 | PM8003 | Phase 2 Clinical | Solid tumours | Details | |
| PM-1003 | PM1003 | Phase 2 Clinical | Solid tumours | Details | |
| IMM-2510 | IMM-2510; SYN-2510 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
| Sotiburafusp alfa | HB0025; HB-0025 | Phase 2 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Kidney Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| HLX-301 | HLX-301 | Phase 2 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms | Details |
| ADG-104 | ADG-104; ADG104 | Phase 2 Clinical | Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc | Neoplasms | Details |
| 6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma, Renal Cell; Myelodysplastic Syndromes; Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Lung Neoplasms | Details |
| Recombinant anti-PD-L1/TGF-β bispecific antibody | Y101D; Y-101D | Phase 2 Clinical | Wuhan Yzy Biopharma Co Ltd | Solid tumours; Pancreatic Neoplasms; Carcinoma, Hepatocellular | Details |
| Carrizumab | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma | Details | |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| FH-2001 | FH-2001 | Phase 2 Clinical | Shanghai Fosun Pharmaceutical Industrial Development Co Ltd | Solid tumours | Details |
| INCB-099280 | INCB-099280; INCB-99280 | Phase 2 Clinical | Incyte Corp Ltd | Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Mismatch Repair Deficient Cancer; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Neoplasms; Microsatellite instability-high cancer; Mesothelioma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma | Details |
| QLF31907 | QLF31907; QLF-31907 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma | Details |
| IBC-0966 | IBC-0966 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Neoplasms | Details |
| LBL-024 | LBL024; LBL-024 | Phase 2 Clinical | Nanjing WeiLibo biological Technology Co Ltd | Solid tumours; Neoplasms; Carcinoma, Neuroendocrine | Details |
| BAT-7104 | BAT-7104 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
| BCD-106 | BCD-106 | Phase 2 Clinical | BIOCAD JSC | Solid tumours | Details |
| PM-1022 | PM-1022 | Phase 2 Clinical | Neoplasms | Details | |
| HB-0028 | HB-0028 | Phase 2 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours; Uterine Cervical Neoplasms | Details |
| 99mTc-NM-01 | 99mTc-NM-01 | Phase 2 Clinical | Nanomab Technology Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Solid tumours; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma | Details |
| LB-1410 | LB-1410 | Phase 2 Clinical | L&L Biopharma Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
| sirpiglenastat | DRP-104 | Phase 2 Clinical | Dracen Pharmaceuticals Inc | Solid tumours; Fibrolamellar hepatocellular carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| AP-505 | AP-505; B1962; AP505 | Phase 2 Clinical | AP Biosciences Inc | Solid tumours; Liver Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| 18F-BMS-986229 | 18F-BMS-986229; [18F]BMS-986229 | Phase 2 Clinical | Bristol-Myers Squibb International Corp, PeptiDream Inc | Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| 6MW-3511 | 6MW-3511 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
| AB-001 (Agastiya Biotech) | AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech); AB01 (Agastiya Biotech) | Phase 2 Clinical | Agastiya Biotech LLC | Neoplasms | Details |
| LB-101 (Centessa Pharmaceuticals) | LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody | Phase 2 Clinical | Centessa Pharmaceuticals Plc | Solid tumours | Details |
| BPB-101 | BPB-101 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| Pacmilimab | CX-072 | Phase 2 Clinical | Cytomx Therapeutics Inc | Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Lymphoma; Melanoma | Details |
| PRS-344 | PRS-344S095012; S-095012; S-95012; PRS-344/ONC0055; PRS-344; PRS-344/S095012 | Phase 2 Clinical | Pieris Pharmaceuticals Inc | Solid tumours | Details |
| MAX-80391 | MAX-80391; MAX-8 | Phase 2 Clinical | Beijing Re Ji Medical Technology Co Ltd | Solid tumours | Details |
| JSKN-033 | JSKN033; JSKN-033; JSKN-003/Envafolimab | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Solid tumours; Neoplasms | Details |
| IO-120/ IO-103 (IO Biotech) | IO-120/IO-103; IO-120+IO-103 | Phase 2 Clinical | Io Biotech Inc | Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| DB-1419 | DB-1419 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours | Details |
| HB-0036 | HB-0036 | Phase 2 Clinical | HuaBo Biopharm Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| AP-203 | AP-203; AP203 | Phase 2 Clinical | AP Biosciences Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| HLX-43 | HLX-43; HLX43 | Phase 2 Clinical | Shanghai Henlius Biotech Inc | Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
| Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) | LP-002 | Phase 2 Clinical | Taizhou Houde Aoke Technology Co Ltd | Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma | Details |
| Danburstotug | STI-3031; STI-A1015; IMC-001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Neoplasm Metastasis | Details |
| 89Zr-durvalumab | Phase 2 Clinical | Radboud University Nijmegen | Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Evixapodlin | GS-4224; OX-4224 | Phase 2 Clinical | Gilead Sciences Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| PM-8001 | 6MW3111; PM-8001 | Phase 2 Clinical | Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital Of Shanghai | Pancreatic Neoplasms | Details | |
| BMS-936559 | MDX-1105; BMS-936559 | Phase 2 Clinical | Bristol-Myers Squibb Company | Leukemia, Myelogenous, Chronic; HIV Infections; Shock, Septic; Hodgkin Disease; Small Cell Lung Carcinoma; Neoplasms; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma | Details |
| RG-6084 | RG-6084; RO-7191863 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Hepatitis B, Chronic; Hepatitis B | Details |
| Vudalimab | XmAb-717; XmAb-20717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Fallopian Tube Neoplasms; Breast Neoplasms; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Astrocytoma; Colorectal Neoplasms; Carcinoma, Neuroendocrine; Endometrial Neoplasms; Cholangiocarcinoma; Thymoma; Carcinoma, Squamous Cell; Castration-Sensitive Prostate Neoplasms; Thyroid Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Ovarian Neoplasms; Solid tumours; Rectal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Esophageal Neoplasms; Stomach Neoplasms; Small Cell Lung Carcinoma; Biliary Tract Neoplasms; Colonic Neoplasms; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Mesothelioma; Microsatellite instability-high cancer; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant | Details |
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| RC-98 | RC-98; RC98; RC98-ADC | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours; Stomach Neoplasms | Details |
| PD-L1 t-haNK cell therapy | Phase 2 Clinical | Nantkwest Inc | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Glioblastoma; Pancreatic Neoplasms; Neoplasm Metastasis | Details | |
| MAX-10181 | MAX-10181; MAX-1 | Phase 2 Clinical | Beijing Re Ji Medical Technology Co Ltd | Solid tumours; Neoplasms; Glioma | Details |
| FAZ-053 | FAZ-053; LAE-005; LAE005 | Phase 2 Clinical | Novartis Pharma Ag | Solid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part | Details |
| PM-8002 | PM8002; PM-8002; BNT-327 | Phase 3 Clinical | Biotheus Inc | Solid tumours; Liver Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Triple Negative Breast Neoplasms; Neuroendocrine Tumors; Mesothelioma; Breast Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| HL-301 | HL-301 | Phase 3 Clinical | Hanmi Pharmaceutical Co Ltd | Radiation Pneumonitis; Acute Bronchitis; Pulmonary Disease, Chronic Obstructive; Lung Neoplasms | Details |
| Acasunlimab | PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 | Phase 3 Clinical | Genmab A/S, Biontech Se | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Erfonrilimab | KN-046; KN046; KNO-46 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Lymphoma; Thymoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Thymus Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Colonic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours | Details |
| Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Brain metastases; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Thymus Neoplasms; Oropharyngeal Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Lymphoma; Penile Neoplasms; Thymoma; Urogenital Neoplasms; Metastatic breast cancer; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Sarcoma, Kaposi; Neoplasms, Germ Cell and Embryonal; Stomach Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Vaginal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Anus Neoplasms; Biliary Tract Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Nose Neoplasms; Ganglioglioma; Papillomavirus Infections; Carcinoma, Trans | Details |
| PD-1 Inhibitor Therapy(Hunan Cancer Hospital) | Hunan Cancer Hospital | Details | |||
| Treprilimab | Clinical | Sun Yat-Sen University | Oropharyngeal Neoplasms | Details | |
| INSIX RA (Indus Biotech) | Clinical | Indus Biotech Pvt Ltd | Arthritis, Rheumatoid; Inflammation | Details | |
| 64Cu-DOTA-nivolumab (Bristol-Myers Squibb/Ono Pharmaceutical) | Clinical | Ono Pharmaceutical Co Ltd, Bristol-Myers Squibb Company | Melanoma; Carcinoma, Non-Small-Cell Lung | Details | |
| Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) | Phase 1 Clinical | Anhui Korton Biological Technology Co Ltd | Esophageal Neoplasms; Carcinoma, Hepatocellular | Details | |
| STW204 | STW-204; AI025; AI-025 | Phase 1 Clinical | Suzhou Stainwei Biotech Inc | Solid tumours; Neoplasms | Details |
| MW-11 | MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111 | Phase 1 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Breast Neoplasms | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) | Phase 1 Clinical | Shanxi Weiqidaguangming Pharmaceutical Co Ltd | Solid tumours | Details | |
| αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd) | BZDS1901; BZDS-1901; BZD1901 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Ovarian Neoplasms; Solid tumours; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| VT1093 | VT1093; VT-1093 | Phase 1 Clinical | Beijing Weiyuan Likang Biotechnology Co Ltd | Solid tumours | Details |
| NWY-001(Biocytogen Pharmaceuticals) | NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals) | Phase 1 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd | Solid tumours; Hematologic Neoplasms; Neoplasms | Details |
| IBI-319 | IBI-319 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Neoplasms | Details |
| GNR-051 | GNR-051 | Phase 1 Clinical | Generium Pharmaceuticals | Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| JS-201 | JS-201 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Neoplasms | Details |
| PH762-TME | RXI 762-ACT; mPH-762; PH-762; PH762-ACT | Phase 1 Clinical | Phio Pharmaceuticals Corp | Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Melanoma | Details |
| IBI-321 | IBI-321 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular | Details | |
| Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) | Bis-5 | Phase 1 Clinical | L&L Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
| SSGJ-705 | 705; SSGJ-705 | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Solid tumours; Neoplasms | Details |
| SHR-1901 | SHR-1901 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Neoplasms | Details |
| CA-170 | CA-170; AUPM-170 | Phase 1 Clinical | Aurigene | Solid tumours | Details |
| Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) | Phase 1 Clinical | Dongguan City Hec Biological Medicine Res And Development Co Ltd | Stomach Neoplasms; Esophageal adenocarcinoma | Details | |
| Latikafusp | AMG-256 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| 706-3SBio | SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody | Phase 1 Clinical | 3sbio Inc | Solid tumours; Composite Lymphoma; Neoplasms; Lymphoma | Details |
| 89Zr-N-sucDf-pembrolizumab | Phase 1 Clinical | Merck & Co Inc, Umcg The University Medical Center Groningen | Melanoma; Carcinoma, Non-Small-Cell Lung | Details | |
| AK-131 | AK-131 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
| CDX-585 | CDX-585; BSI-585 | Phase 1 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd, Celldex Therapeutics | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ABBV-1882 | ABBV-1882 | Phase 1 Clinical | Abbvie Inc | HIV Infections | Details |
| Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University) | Phase 1 Clinical | Sun Yat-Sen University | Hematologic Neoplasms; Nasopharyngeal Carcinoma | Details | |
| SOT-201 | SOT-201; SO C108; SO-C108 | Phase 1 Clinical | Sotio | Solid tumours; Neoplasms | Details |
| Sym-024 | Sym-024; S-95024 | Phase 1 Clinical | Symphogen A/S | Solid tumours; Neoplasm Metastasis | Details |
| KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| JNJ-67484703 | JNJ-67484703; JNJ-4703 | Phase 1 Clinical | Janssen Research & Development Llc | Arthritis, Rheumatoid | Details |
| BC008-1A | BC008-1A | Phase 1 Clinical | Sichuan Luzhou Buchang Biopharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Glioblastoma; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
| TC-N201(TCRCure) | TC-N201 | Phase 1 Clinical | Tcrcure Biopharma Ltd | Solid tumours | Details |
| WTX-212 | WTX-212 | Phase 1 Clinical | Westlake Therapeutics | Solid tumours; Hematologic Neoplasms; Neoplasms; Lung Neoplasms | Details |
| SV-102 | SV-102; SV102; SYNC-T SV-102 | Phase 1 Clinical | Syncromune Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| INCA33890 | INCA33890; INCA-33890 | Phase 1 Clinical | Incyte Corp | Solid tumours | Details |
| STW204/Gotistobart | AI-061 | Phase 1 Clinical | Oncoc4 Inc | Colorectal Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms | Details |
| WTX-212A | WTX-212A; WTX212A | Phase 1 Clinical | Zhejiang University | Solid tumours | Details |
| HC-010(Shanghai Hongcheng) | HC-010; HC010 | Phase 1 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Solid tumours | Details |
| BPT-567 | BPT-567 | Phase 1 Clinical | Bright Peak Therapeutics Inc | Solid tumours; Neoplasms | Details |
| PD 1-proIL-2v (Proviva Therapeutics) | PTX-912 | Phase 1 Clinical | Proviva Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| BZE-2209 | BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Solid tumours | Details |
| BZT-2312 | BZT-2312; Fast CAR T cells | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Solid tumours | Details |
| CS-2009 | CS-2009 | Phase 1 Clinical | Cstone Pharmaceuticals | Solid tumours; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| CD-001 | CD-001 | Phase 1 Clinical | CD (Suzhou) Biopharma Co Ltd | Solid tumours; Hematologic Neoplasms; Neoplasms | Details |
| γδ T-PD-1 Ab Cells therapy(Changzhou No.2 People’S Hospital) | Phase 1 Clinical | Changzhou No.2 People’S Hospital | Solid tumours | Details | |
| TQB-2252 | TQB-2252; TQB2252 | Phase 1 Clinical | Chia Tai Tianqing (Guangzhou) Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| MAQ-001 | MAQ-001 | Phase 1 Clinical | MabQuest SA | Solid tumours | Details |
| FP-008 (Fapon Biotech) | FP-008; FP008 | Phase 1 Clinical | Fapon Biotech Inc | Neoplasms | Details |
| GenSci-120 | GenSci-120; GenSci120 | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Sjogren's Syndrome; Autoimmune Diseases; Graft vs Host Disease; Lupus Erythematosus, Systemic | Details |
| JMT-108 | JMT108; JMT-108 | Phase 1 Clinical | Shanghai Jmt-Bio Inc | Neoplasms | Details |
| TEV-278 | TEV-278; TEV-‘278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | Neoplasms | Details |
| ONO-4915 | ONO-4915 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Autoimmune Diseases | Details |
| Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company | Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| CTX-8371 | CTX-8371 | Phase 1 Clinical | Compass Therapeutics LLC | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Hodgkin Disease; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| MVR-C5252 | C-5252; MVR-C5252; T-5 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms; Glioma | Details |
| ASKG-915 | ASKG-915 | Phase 1 Clinical | Askgene Pharma | Solid tumours; Neoplasms | Details |
| Mableukin 2PD1 (Anwita Biosciences) | AWT020; AWT-020 | Phase 1 Clinical | Anwita Biosciences Inc | Solid tumours; Carcinoma, Renal Cell; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Autoimmune Diseases of the Nervous System | Details |
| GS-0151 | GS-0151; MB-151 | Phase 1 Clinical | University Of Oxford | Autoimmune Diseases; Inflammation | Details |
| iCasp9M28z T cells | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Mesothelioma; Breast Neoplasms; Lung Neoplasms | Details | |
| rHSV-1-APD1 | YST-02 | Phase 1 Clinical | Xiamen University | Solid tumours; Neoplasms; Central Nervous System Neoplasms; Glioma | Details |
| MHC-001 | MHC-001 | Phase 1 Clinical | Sichuan University | Carcinoma, Non-Small-Cell Lung | Details |
| Sofusa anti-PD-1 | Phase 1 Clinical | Sorrento Therapeutics Inc | Lymphoma, T-Cell, Cutaneous | Details | |
| Yinkang-001 | Phase 1 Clinical | Solid tumours | Details | ||
| Taminadenant | NIR-178; PBF-509 | Phase 1 Clinical | Palobiofarma Sl | Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Nivolumab biosimilar (Mabpharm) | CMAB8-19; CMAB-819 | Phase 1 Clinical | Sinomab Bioscience Ltd | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| RB-0004 | RB-0004 | Phase 1 Clinical | Reyoung Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
| ONO-4685 | ONO-4685 | Phase 1 Clinical | Merus Nv | Lymphoma, T-Cell; Plaque psoriasis; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Sym-021 | Sym-021; S-95016; Sym021 | Phase 1 Clinical | Symphogen A/S | Solid tumours; Lymphoma; Neoplasm Metastasis | Details |
| Izuralimab | XmAb-23104; XmAb-104 | Phase 1 Clinical | Xencor Inc | Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Solid tumours; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell | Details |
| EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | University Of Pennsylvania, Novartis Pharma Ag | Glioblastoma | Details |
| Eciskafusp Alfa | RO-7284755; RG-6279; PD1-IL2v | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Solid tumours; Urinary Bladder Neoplasms | Details |
| CC-90006 | C-90006; CC-90006 | Phase 1 Clinical | Anaptysbio Inc | Autoimmune Diseases; Psoriasis | Details |
| Zeluvalimab | AMG-404 | Phase 1 Clinical | Amgen Inc | Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Fidasimtamab | IBI-315; BH-2950 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| SYN-125 | SYN-125 | Phase 1 Clinical | Synermore Biologics (Suzhou) Co Ltd | Solid tumours; Carcinoma | Details |
| Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) | Phase 1 Clinical | Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Liver Diseases | Details | |
| GX-P1 | GX-P1; PD-L1 hyfc | Phase 1 Clinical | Genexine Inc | Autoimmune Diseases; Rejection of organ transplantation | Details |
| Recombinant human PD-1 antibody herpes simplex virus | Phase 1 Clinical | Yangsheng Tang Co Ltd, Xiamen University | Head and Neck Neoplasms; Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular | Details | |
| HX-009 | HX-009; HX009-II-02 | Phase 2 Clinical | Waterstone Hanxbio Pty Ltd | Solid tumours; Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Bile Duct Neoplasms; Lymphoma; Melanoma | Details |
| PD-1 knockout engineered T cells (Chengdu MedGenCell) | Phase 2 Clinical | West China Hospital Of Sichuan University, Chengdu Medgencell | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details | |
| Lipustobart | LZM-009 | Phase 2 Clinical | Livzon(Group) Pharmaceutical Factory | Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung | Details |
| Acrixolimab | YBL-006; YBL 006 | Phase 2 Clinical | Y-biologics Inc | Solid tumours | Details |
| RC-148 | RC-148 | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| EMB-02 | EMB-02 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours | Details |
| IMU-201 | IMU-201; APi-2568; KEY-Vaxx; PD1-Vaxx | Phase 2 Clinical | Imugene Ltd | Adenocarcinoma of Lung; Carcinoma, Large Cell; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| LBL-015 | LBL-015 | Phase 2 Clinical | Nanjing WeiLibo biological Technology Co Ltd | Solid tumours; Neoplasms | Details |
| Pradusinstobart | LVGN-3616; SSI-361 | Phase 2 Clinical | Lyvgen Biopharma(HK)Ltd | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Papillomavirus Infections; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis | Details |
| Pidilizumab | MDV-9300; CT-011 | Phase 2 Clinical | Curetech Ltd | Lymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Colonic Neoplasms; Pancreatic Neoplasms; Multiple Myeloma; Primary mediastinal B cell lymphoma; Sarcoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic | Details |
| TQB-2868 | TQB-2868 | Phase 2 Clinical | Neoplasms; Pancreatic Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details | |
| Rosnilimab | ANB-030 | Phase 2 Clinical | Anaptysbio Inc | Alopecia Areata; Arthritis, Rheumatoid; Colitis, Ulcerative | Details |
| IAP-0971 | IAP-0971 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AK-129 | AK-129 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Neoplasms; Adenocarcinoma | Details |
| HerinCAR-PD1 | Phase 2 Clinical | Ningbo Cancer Hospital | Solid tumours | Details | |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| EBV-specific TCR-T cell with anti-PD1 auto-secreted element | Phase 2 Clinical | Tcrcure Biopharma Ltd | Squamous Cell Carcinoma of Head and Neck | Details | |
| 707 (3SBio) | SSGJ-707; SSGJ707; 707 | Phase 2 Clinical | 3sbio Inc | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| IBI-363 | IBI-363 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Mucosal Melanoma; Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Peramprizumab | Phase 2 Clinical | Sun Yat-Sen University | Nasopharyngeal Carcinoma | Details | |
| SAR-445877 | SAR445877; SAR-445877; KD050; KD-050 | Phase 2 Clinical | Sanofi, Kadmon Corporation Llc | Solid tumours | Details |
| OSE-279 | OSE-279 | Phase 2 Clinical | Ose Immunotherapeutics | Solid tumours; Lymphoma | Details |
| PD-1 Inhibitor Therapy (Gene Key Life) | Phase 2 Clinical | Beijing Gene Key Life Technology Co Ltd | Carcinoma, Hepatocellular | Details | |
| PD-1 Monoclonal Antibody(Sixth Affiliated Hospital Sun Yat-Sen University) | Phase 2 Clinical | Sixth Affiliated Hospital Sun Yat-Sen University | Nasopharyngeal Neoplasms; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms | Details | |
| Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms | Details | |
| MHB-039-A | MHB039A; MHB-039-A | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Solid tumours; Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
| PD-1 inhibitor therapy(Shanghai Chest Hospital) | Phase 2 Clinical | Shanghai Chest Hospital | Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma | Details | |
| PD-1 Inhibitor Therapy(Affiliated Hospital of Nantong University) | Phase 2 Clinical | Affiliated Hospital Of Nantong University | Esophageal Squamous Cell Carcinoma | Details | |
| SCTB-14 | SCTB14; SCTB-14 | Phase 2 Clinical | SinoCelltech Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| Ezabenlimab | BI-754091 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Sarcoma; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Neuroendocrine; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours; Soft Tissue Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Head and Neck Neoplasms | Details |
| Recombinant human anti-PD-1 monoclonal antibody(CSPC Zhongqi Pharma) | Phase 2 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details | |
| Anti-PD-1 Antibody(Jiangxi Provincial Cancer Hospital) | Phase 2 Clinical | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | Details | |
| LM-299 | LM299; LM-299 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours; Neoplasms | Details |
| SCTB-41 | SCTB41; SCTB-41; SCT-B41 | Phase 2 Clinical | SinoCelltech Ltd | Solid tumours | Details |
| HY-07121 | HY-07121; HY07121 | Phase 2 Clinical | Sichuan Huiyu Seacross Pharma Technology Ltd | Solid tumours | Details |
| AI-081 | AI-081 | Phase 2 Clinical | Oncoc4 Inc | Solid tumours | Details |
| BPT-958 | BPT-958; BPT958 | Phase 2 Clinical | Bright Peak Therapeutics Inc | Neoplasms | Details |
| Sabestomig | AZD-7789 | Phase 2 Clinical | AstraZeneca Ag | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| JS-207 | JS-207 | Phase 2 Clinical | Dotbio Pte Ltd | Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| TY-101 | TY-101; TY101 | Phase 2 Clinical | Tayu Huaxia Biotech Medical Group Co Ltd | Solid tumours; Lymphoma | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| T-3011 | T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015 | Phase 2 Clinical | Immvira Co Ltd | Sarcoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Colorectal Neoplasms; Breast Neoplasms; Solid tumours; Urinary Bladder Neoplasms; Mesothelioma; Ascites; Skin Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Liver Neoplasms; Head and Neck Neoplasms | Details |
| ZG-005 | ZG-005 | Phase 2 Clinical | Gensun Biopharma Inc | Solid tumours; Bile Duct Neoplasms; Lymphoma; Carcinoma, Neuroendocrine; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
| MiHA-loaded PD-L silenced DC vaccination (Radboud University) | Phase 2 Clinical | Radboud University Nijmegen | Hematologic Neoplasms; Colorectal Neoplasms | Details | |
| Lomvastomig | RG-7769; RO-7121661; R07121661 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Peresolimab | LY-3462817 | Phase 2 Clinical | Eli Lilly And Company | Autoimmune Diseases; Arthritis, Rheumatoid; Connective Tissue Diseases; Joint Diseases; Immune System Diseases; Musculoskeletal Diseases; Psoriasis; Rheumatic Diseases; Arthritis | Details |
| PD-1 knockout EBV-CTL (Nanjing Medical University) | Phase 2 Clinical | Nanjing Medical University | Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma | Details | |
| Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Adenocarcinoma, Clear Cell; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Hormone-Resistant Prostate Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Ovarian Clear Cell Carcinoma; Carcinoma, Renal Cell; Solid tumours; Skin Melanoma | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) | 609-A; SSGJ-609A; SSGJ-609-A | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Solid tumours; Sarcoma; Breast Neoplasms | Details |
| Danvilostomig | SI-B003 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma | Details |
| Tobemstomig | RO-7247669 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Liver Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| MAX-10181 | MAX-10181; MAX-1 | Phase 2 Clinical | Beijing Re Ji Medical Technology Co Ltd | Solid tumours; Neoplasms; Glioma | Details |
| Pimivalimab | JTX-4014 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
| PE0105 | PE-0105 | Phase 2 Clinical | Shanghai Yunyi Health Technology Development Co Ltd | Solid tumours; Neoplasms | Details |
| Spartalizumab | PDR-001 | Phase 3 Clinical | Novartis Pharma Ag | Lung Neoplasms; Neuroendocrine Tumors; Uveal melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Breast Neoplasms; Cholangiocarcinoma; Sarcoma; Prostatic Neoplasms; Colorectal Neoplasms; Bone Marrow Diseases; Gastrointestinal Stromal Tumors; Primary Myelofibrosis; Sarcoma, Alveolar Soft Part; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Digestive System Neoplasms; Lymphoma; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Metastatic breast cancer; Esophageal adenocarcinoma; Endometrial Neoplasms; Thyroid Neoplasms; Uterine Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Thrombocythemia, Essential; Uterine Cervical Neoplasms; Adenocarcinoma; Persistent Fetal Circulation Syndrome; Pancreatic Neoplasms; Leukemia; Kidney Neoplasms; Solid tumours; Liver Neoplasms; Preleukemia; Hematologic Diseases; Ovarian Neoplasms; Skin Melanoma; Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Polycythemia Vera; Anus Neopla | Details |
| Nivolumab biosimilar (Shandong Boan Biotechnology) | LY-01015; BA-1104 | Phase 3 Clinical | Shandong Boan Biotechnology Co Ltd | Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Glioma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Mavezelimab/Pembrolizumab | MK-4280A; MK-4820A | Phase 3 Clinical | Merck Sharp & Dohme Corp | Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Neoplasm Metastasis | Details |
| Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co Ltd | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
| Rilvegostomig | AZD-2936 | Phase 3 Clinical | Astrazeneca Plc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Pembrolizumab/Vibostolimab | MK-7684A | Phase 3 Clinical | Merck & Co Inc | Cholangiocarcinoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Hematologic Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Ovarian Neoplasms | Details |
| Hyaluronidase/Pembrolizumab | MK-3475A | Phase 3 Clinical | Merck Sharp & Dohme Corp | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Pembrolizumab biosimilar (biocad) | BCD-201 | Phase 3 Clinical | BIOCAD JSC | Skin Melanoma; Solid tumours; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Nivolumab biosimilar(Amgen) | ABP-206 | Phase 3 Clinical | Amgen Inc | Melanoma | Details |
| Pembrolizumab biosimilar (Qilu) | QL2107; QL-2107 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma | Details |
| PD-1 Inhibitor Therapy(Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) | Phase 3 Clinical | Sun Yat-Sen Memorial Hospital Of Sun Yat-Sen University | Squamous Cell Carcinoma of Head and Neck; Rejection of liver transplantation; Carcinoma, Hepatocellular | Details | |
| BAT-3306 | BAT3306; BAT-3306 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Pembrolizumab Biosimilar(Sandoz) | GME-751; GME751 | Phase 3 Clinical | Sandoz | Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Nivolumab biosimilar (Biocad) | BCD-263 | Phase 3 Clinical | BIOCAD JSC | Skin Melanoma; Melanoma | Details |
| Pembrolizumab biosimilar (Shanghai Henlius Biotech Inc) | HLX-17 | Phase 3 Clinical | Shanghai Henlius Biotech Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| Pembrolizumab Biosimilar (Samsung Bioepis ) | SB27; SB-27 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Pembrolizumab biosimilar(R-Pharm) | RPH-075 | Phase 3 Clinical | R-Pharm | Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details |
| Pembrolizumab biosimilar (Laboratorio Elea Phoenix Sa) | MB-12; MB12 | Phase 3 Clinical | Laboratorio Elea Phoenix Sa | Carcinoma, Non-Small-Cell Lung | Details |
| Pembrolizumab biosimilar (Amgen) | ABP 234; ABP-234 | Phase 3 Clinical | Amgen Inc | Carcinoma, Non-Small-Cell Lung | Details |
| Pembrolizumab biosimilar (Celltrion) | CT-P51 | Phase 3 Clinical | Celltrion Inc | Stomach Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Nivolumab biosimilar(Sandoz) | JPB898; JPB-898 | Phase 3 Clinical | Sandoz | Melanoma | Details |
| Atigotatug/Nivolumab | BMS-986489 | Phase 3 Clinical | Bristol-Myers Squibb Company | Small Cell Lung Carcinoma | Details |
| Pembrolizumab biosimilar(Formycon) | FYB-206 | Phase 3 Clinical | Formycon AG | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Rulonilimab | F-520 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, T-Cell, Peripheral; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Central Nervous System Lymphoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
| Tebotelimab | PD-1 X LAG-3; MGD-013 | Phase 3 Clinical | Macrogenics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms | Details |
| Nurulimab/Prolgolimab | BCD-217; BCD-145/BCD-100 | Phase 3 Clinical | BIOCAD JSC | Skin Melanoma; Melanoma | Details |
| Volrustomig | MEDI-5752; MEDI5752 | Phase 3 Clinical | Medimmune Llc | Biliary Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Sarcoma; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
| Genolimzumab | CBT-501; APL-501; APL501; GB226; GB-226 | Phase 3 Clinical | Cbt, Genor Biopharma Co Ltd, Apollomics Inc | Thymus Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Thymoma; Neoplasms, Unknown Primary; Sarcoma, Alveolar Soft Part; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell, Peripheral; Colorectal Neoplasms; Microsatellite Instability; Hodgkin Disease; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Lymphoma, B-Cell; Solid tumours | Details |
| BAT-1308 | BAT-1308 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
| Sasanlimab | RN-888; PF-06801591; PF-6801591 | Phase 3 Clinical | Pfizer Inc | Carcinoma, Squamous Cell; Neoplasms, Glandular and Epithelial; Urinary Bladder Neoplasms; Urologic Diseases; Sarcoma; Prostatic Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Carcinoma, Pancreatic Ductal; Kidney Diseases; Endometrial Neoplasms; Urogenital Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Fructose Intolerance; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Renal Cell; Ovarian Neoplasms; Head and Neck Neoplasms; Skin Melanoma; Lymphoma, T-Cell, Peripheral; Kidney Neoplasms; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse | Details |
| Nofazinlimab | CS-1003 | Phase 3 Clinical | Cstone Pharmaceuticals | Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular | Details |
| Iparomlimab | QL1604; QL-1604; PSB-103 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Liver Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma | Details |
| Cetrelimab | JNJ-63723283; JNJ-3283 | Phase 3 Clinical | Johnson & Johnson | Solid tumours; Hepatitis B, Chronic; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Budigalimab | ABBV-181 | Phase 3 Clinical | Abbvie Inc | Solid tumours; HIV Infections; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email:order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved